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Inherited growth-hormone insensitivity (GHI) is a heterogeneous disorder that is often caused by mutations in the
coding exons or flanking intronic sequences of the growth-hormone receptor gene (GHR). Here we describe a novel
point mutation, in four children with GHI, that leads to activation of an intronic pseudoexon resulting in inclusion
of an additional 108 nt between exons 6 and 7 in the majority of GHR transcripts. This mutation lies within the
pseudoexon (A51rG51 at the 5
′ pseudoexon splice site) and, under in vitro splicing conditions, results in inclusion
of the mutant pseudoexon, whereas the wild-type pseudoexon is skipped. The presence of the pseudoexon results
in inclusion of an additional 36–amino acid sequence in a region of the receptor known to be involved in homo-
dimerization, which is essential for signal transduction.
Inclusion of intronic sequences by aberrant splicing is a
common cause of genetic disease (Krawczak et al. 1992).
This usually occurs through the creation or activation of
a splice site within 100 nt of the normally used splice site
(Nakai and Sakamoto 1994), as a result of a point mu-
tation in the genomicDNA sequence. Suchmutations lead
to the inclusion of intronic sequences immediately flank-
ing the exonic sequence. IntronicDNA frequently encodes
potential exonic sequences (Dunham et al. 1999)—so-
called “pseudoexons” (Sun and Chasin 2000)—that are
not recognized by the splicing machinery.
Patients with growth-hormone insensitivity (GHI
[MIM 600946 and MIM 245590]) express a variable
phenotype. The most severe form, Laron syndrome
(MIM 262500), is characterized by severe growth re-
tardation and dysmorphic facial features, associated
with elevated circulating growth hormone (GH) and
subnormal levels of insulin-like growth factor 1 (IGF-
1), IGF-binding protein 3 (IGFBP3), and acid-labile sub-
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unit (Savage et al. 1993). Levels of GH-binding protein
(GHBP), the soluble extracellular domain of the GHR,
are low or undetectable in 80% of cases (Buchanan et
al. 1991; Woods et al. 1997), reflecting defective GHR
expression or defective ligand binding as the underlying
cause of the disease. In cases of partial or atypical GHI,
GHBP levels and facial appearance are often normal,
and growth retardation is less severe (Attie et al. 1995;
Goddard et al. 1995; Carlsson 1996). Mutations within
the GHR have frequently been implicated as the cause
of GHI.
The present study concerns one highly consanguin-
eous Pakistani kindred with four male individuals af-
fected with atypical GHI (fig. 1). The four patients (two
pairs of siblings) have marked short stature. The stan-
dard deviation score (SDS)—an indicator of height that
is independent of age, is appropriate for the population
under study, and reflects the divergence from the mean—
was found to be 3.3 to 5.6 in these children. In
addition, there were low levels of IGF-1 (20–29 ng/ml
[normal level 150 ng/ml]), detectable levels of GHBP
(28.1%–51.7% [normal range 14.1%–42.9%]), and a
normal facial appearance. Homozygosity mapping of
several polymorphic markers surrounding the GHR
identified, in all four patients, a homozygous region that
was absent in their unaffected siblings. This region (13
cM) spanned three markers (D5S2022, D5S634, and
D5S628; fig. 1). In addition, six nucleotide polymor-
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Figure 1 Homozygosity mapping. The pedigree of the consanguineous Pakistani family is shown. Black and white symbols denote
affected and unaffected individuals, respectively. D5S628, D5S634, and D5S2022 dinucleotide repeat markers were amplified by PCR,
and resultant fragments were electrophoresed on a 5% PAGE gel on an ABI 377 automated sequencer; analysis was performed using
Genescan software (Applied Biosystems). The complex single polymorphic region in intron 9 of GHR was sequenced using the ABI
Prism Big Dye Sequencing kit and an ABI 377 automated DNA sequencer (Applied Biosystems), in accordance with the manufacturer’s
instructions. Genotypes of this region are indicated by Roman numerals, as defined by Amselem et al. (1989).
phisms in intron 9 of the GHR (Amselem et al. 1989)
were investigated by PCR and direct sequencing and
were found to be homozygous in all four patients but
not in other family members (GHR int 9; fig. 1). Se-
quencing of the coding exons flanking splice junctions
and branch point sequences showed no mutations. We
therefore hypothesized that the defect was either within
one of the introns of the GHR or within another gene
closely linked to it.
GHR mRNA transcripts in fibroblasts from patients
and from control subjects were investigated by reverse-
transcriptase PCR (RT-PCR). Two nested amplifications
were performed. First-round primers were directed to
exons 2 and 10, and second-round primers were directed
either to exons 6 and 7 or to exons 6 and 10 of the
GHR. In cDNA from control fibroblasts, the only prod-
ucts were of the expected size (fig. 2A, lanes 3 [574 bp]
and 5 [320 bp]), whereas in cDNA from patient samples,
a larger band was produced (fig. 2A, lanes 2 [682 bp]
and 4 [428 bp]) in addition to the much less abundant
band of the expected size. Direct sequencing of each
product was performed, revealing that the fragments of
the expected size for both patient and control samples
corresponded to the predicted mRNA sequence. The
larger fragments seen in patient cDNA contained a 108-
bp insertion between exons 6 and 7.
The novel 108-bp inserted sequence did not match the
sequence flanking either exon 6 or 7, implying that the
sequence was derived either from activation of a pseudo-
exon (6w) within intron 6 or from an exon introduced
into the intron by a recombination event. We use the
term “pseudoexon” to indicate a potential exon, con-
taining adequate 5′ and 3′ splice sites, that is not nor-
mally spliced into mature mRNA by the cellular splicing
machinery (Sun and Chasin 2000). To ascertain the po-
sition of the new sequence, long PCR was performed to
span intron 6 in patient and control DNA samples. In-
tron 6 is 11 kb in length, and 6w is located 1.7 kb from
exon 6 (fig. 2B). This sequence has not been reported
previously and has now been deposited in GenBank (ac-
cession numbers AF344653 and AF344654). Analysis
by PCR and sequencing of a 650-bp fragment spanning
6w from a control genomic DNA sample revealed that
6w was flanked by 5′ and 3′ splice sites. Patient DNA
was found to have a homozygous base change (ArG)
at the last nucleotide of the pseudoexon (fig. 2B). The
parents and several unaffected siblings were heterozy-
gous for the mutation but were of normal stature, as
was a single sibling who was homozygous for the wild-
type A allele. The mutation was not detected by mini-
sequencing (SnaPshot, Applied Biosystems) in 100 un-
related control chromosomes of similar ethnic origin.
To ascertain whether this base change was necessary
and sufficient for 6w inclusion in transcription, we in-
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Figure 2 Pseudoexon inclusion demonstrated in cDNA from a patient, but not from a control. A, mRNA was extracted from
patient and control skin fibroblasts, and cDNA was generated using MMLTV reverse transcriptase (Promega). PCR amplification was
achieved by a nested PCR, using primers in exons 2 and 10 in first rounds and 6 and 10 (lanes 2 and 3) or 6 and 7 (lanes 4 and 5) in
second rounds. Products obtained from the patient (P) or control (C) are indicated above the lanes. Sizes (in bp) of the markers (M)
are given on the left of the gel, and sizes of the PCR products are given on the right. B, Scheme of the genomic structure between exons
6 and 7, derived from long PCR through use of the Extensor Long PCR system (Advanced Biotechnologies). Boxes represent exons, the
dashed box represents the pseudoexon, and horizontal lines represent introns. Intron lengths (in kb) are given above the diagram in
bold type, and exon lengths (in bp) are given below the diagram. The sequences of the wild-type (WT) and mutant (MT) pseudoexon
(in capital letters) and the flanking intronic 5′ splice site (in lowercase letters) is shown below. The slash (/) indicates the cleavage site.
serted the pseudoexon and flanking intronic sequences
into the intron of a well-characterized splicing reporter
derived from the adenovirus major late first and second
leader exons (AdMLpar) (Gozani et al. 1994). Two het-
erologous substrates were made, one containing the
wild-type 6w pseudoexon (AdML-w; fig. 3A) and the
other the mutated 6w exon (AdML-wmt). Under splicing
conditions, the pseudoexon was skipped in AdML-w but
was efficiently included in AdML-wmt (fig. 3B).
Pseudoexon inclusion has previously been reported
only in association with the creation, by mutations in
intronic sequence, of novel splice or branch sites (High-
smith et al. 1994; Wang et al. 1997; Chillon et al. 1995;
De Klein et al. 1998; Vervoort et al. 1998; Dwi Pramono
et al. 2000). By contrast, the wild-type pseudoexon in
this case already possesses a legitimate branch site, 5′
and 3′ splice-site sequences, and the mutation is within
the pseudoexonic sequence itself. The exon 6w muta-
tion changes A1 to G1 at the 5
′ splice site (consensus
G1/G1U2G3A4G5C6, where the slash indicates the cleav-
age site). The mutation brings the sequence closer to
complementarity with U1 snRNP, but the mechanism by
which this causes such a dramatic change in splice-site
selection is unclear. First, an A1 is found in ∼15% of
natural exons (Long et al. 1998). Second, a comparison
between G1 and A1 shows that A1 does not reduce
in vivo splicing efficiency in a constitutively spliced exon
(Aebi et al. 1986) or selection of alternative 5′ splice sites
(Lear et al. 1990). Previous work has shown that the
A1 change increases exon skipping in vitro by only a
small amount (∼15%) (Aebi et al. 1986), whereas exon
skipping is dramatically increased in the wild type 6w
(A-1) when compared with the mutant (G1) (fig. 3B). In
mammals, binding of U1 snRNP to 5′ splice sites does
not correlate well with splicing in vitro (Eperon et al.
1993); however, we hypothesize that the point mutation
improves the interaction of the pre-mRNA with U1
snRNP, resulting in recognition, by the spliceosome, of
the mutant 6w as an exon. This interaction is the subject
of continuing investigation.
The inclusion of 6w is predicted to lead to the insertion
of 36 amino acid residues, between exons 6 and 7, that
will be in-frame and that will lack a stop codon. This
region of the GHR protein is critically involved in re-
ceptor dimerization (Cunningham et al. 1991). It is likely
that disruption of this process—and, hence, failure of
GH signalling—would result from this mutation, as has
been demonstrated with another mutation in this region
(Duquesnoy et al. 1994). Classical GHBP-negative GHI
exhibits a mean height SDS of 6.45 (range 3.0 to
10.4), whereas the height SDS of these subjects was
less severe and more typical of GHBP-positive GHI
(mean 4.89; range 2.2 to 10.4) (Woods et al.
1997). This slightly less severe phenotype of the four
affected boys may be due to a small amount of normally
spliced GHR mRNA (fig. 2A), which produces an en-
tirely normal GHR.
We believe that this is the first demonstration that a
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Figure 3 Pseudoexon inclusion caused by the ArG mutation. A, Structure of the three pre-mRNA substrates used for in vitro
splicing experiments. Solid boxes and lines indicate AdML sequences, and dashed boxes and lines are pseudoexon fragments and flanking
intron. B, In vitro splicing. PCR fragments containing wild-type and mutant pseudoexons and surrounding introns were cloned into
pCR Blunt (Invitrogen), sequenced, and used as further templates for PCR. AdML-w and AdML-wmt were made by overlap-extension
proof-reading PCR, using primers GHR-pe-AdMLpar2-S (5′-ccctcactaaagCAGGAGTATCATGCTGCT) and GHR-pe-AdMLpar2-A (5′-
cttgactactgcTAATGACAAAATTGGCATCT), and primers AdMLpar-int51-S (5′-GCAGTAGTCAA) and AdMLpar-L2-A (5′-ATCCAAG-
AGTACTGGAA), and a second-round PCR with GHR-pe-AdMLpar2-S and AdMLpar-L2-A. The second-round PCR fragment was used
as a megaprimer in a third-round PCR with a T7 primer, using AdMLpar as a template. Assembled AdML-w and AdML-wmt PCR
products were gel purified, cloned into pCR-blunt, and sequenced. Transcription templates were generated by a proof-reading PCR,
with a T7 primer and AdMLpar-L2-A, and capped pre-mRNA transcribed with T7 RNA polymerase in the presence of [32P]-labeled
GTP. Splicing reactions used 20 fmol of RNA, 32% Hela nuclear extract, 0.5 mM ATP, 3.2 mM MgCl2, 2.6% polyvinyl alcohol, and
60 mM KCl at 30C (Chew et al. 2000). Reactions were deproteinized with phenol, precipitated with ethanol, and run on polyacrylamide
gels ranging from 5.5% to 8%, before autoradiography. A representative in vitro splicing experiment is shown. Pre-mRNA substrates
are indicated above the lanes, together with the time of the splicing reactions. The identity of the bands is indicated by the symbols to
the sides of the gel and was confirmed by comparison with AdMLpar, by electrophoresis on higher-percentage gels to shift the lariat-
intermediate, and by isolation of the mRNA from the gel, RT-PCR, and sequencing.
pseudoexonic point mutation is necessary and sufficient
to activate a pseudoexon and cause disease. Mutations
causing pseudoexonic inclusion may be more prevalent
than the current literature suggests; pseudoexonic se-
quences are frequently found within introns (Dunham
et al. 1999), and, in the human hprt gene, pseudoexons
outnumber legitimate exons by as many as 10:1 (Sun
and Chasin 2000). Detection of these events in disease
is hampered since introns, because of their frequently
large size, are often excluded from mutational analyses,
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and it is often impossible or impractical to perform
cDNA analysis.
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